How innate immune mechanisms contribute to antibody-enhanced viral infections
about
IFITM proteins restrict antibody-dependent enhancement of dengue virus infectionFeasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplexAntibody-Dependent Enhancement of Dengue Virus Infection in Primary Human Macrophages; Balancing Higher Fusion against Antiviral ResponsesConvalescent plasma: new evidence for an old therapeutic tool?Subdominant Outer Membrane Antigens in Anaplasma marginale: Conservation, Antigenicity, and Protective Capacity Using Recombinant ProteinConverting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into playChallenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue VaccinesHigh titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza.Changes in hematological and serum biochemical parameters in common marmosets (Callithrix jacchus) after inoculation with dengue virus.Current progress in dengue vaccinesSubversion of early innate antiviral responses during antibody-dependent enhancement of Dengue virus infection induces severe disease in immunocompetent mice.Evidence of dengue virus transmission and factors associated with the presence of anti-dengue virus antibodies in humans in three major towns in CameroonPorcine FcγRIIb mediates enhancement of porcine reproductive and respiratory syndrome virus (PRRSV) infection.Antibody-dependent enhancement infection facilitates dengue virus-regulated signaling of IL-10 production in monocytes.Dengue vaccines: strongly sought but not a reality just yetRespiratory syncytial virus induced type I IFN production by pDC is regulated by RSV-infected airway epithelial cells, RSV-exposed monocytes and virus specific antibodiesFormation of infectious dengue virus-antibody immune complex in vivo in marmosets (Callithrix jacchus) after passive transfer of anti-dengue virus monoclonal antibodies and infection with dengue virus.Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera.A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challengeImmunological mechanisms of vaccination.Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune PotentiatorsImmunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primatesThe cytokine response of U937-derived macrophages infected through antibody-dependent enhancement of dengue virus disrupts cell apical-junction complexes and increases vascular permeability.Resveratrol inhibits the TRIF-dependent pathway by upregulating sterile alpha and armadillo motif protein, contributing to anti-inflammatory effects after respiratory syncytial virus infection.The human antibody response to dengue virus infectionMolecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans.Multiantibody strategies for HIV.Developing a dengue vaccine: progress and future challenges.Type I and type II Fc receptors regulate innate and adaptive immunity.Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.Paper-based point-of-care testing for diagnosis of dengue infections.Progress towards understanding the pathogenesis of dengue hemorrhagic fever.A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.Immunological considerations for developing antibody therapeutics for Influenza A.Dengue Patients with Early Hemorrhagic Manifestations Lose Coordinate Expression of the Anti-Inflammatory Cytokine IL-10 with the Inflammatory Cytokines IL-6 and IL-8.H7N9 influenza: something old, something new ….Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.Intranasal administration of antibody-bound respiratory syncytial virus particles efficiently primes virus-specific immune responses in mice.Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.Noninvasive vaccination as a casus belli to redeem vaccine value in the face of anti-vaccine movements.
P2860
Q24311739-CB781E6D-823D-4ECD-98FE-7BEE66ADCDD6Q24737461-27C04106-1930-4FE5-90A2-C025470E6A77Q25708015-CE066557-2CC6-46A8-AC91-522631D01607Q26775412-773C204E-057A-4665-A930-284880B123CFQ27304777-0692C87C-9C00-48BF-9C8B-9275EB7E92A3Q27468870-52B615A3-85E4-43AB-88B4-DE09CBE5A202Q27468886-F0A009D7-13DA-4684-8606-E97C9BB63360Q30416598-1C1BB171-9E84-4C44-9812-DBC90A0067A4Q33402211-50257D8F-4E03-4193-8143-F88206B2CAB4Q33408300-9CA69189-7A33-4A8A-B973-84D95FAFB4F8Q33414560-0B131744-9423-4233-88B6-75B07A5E3CE1Q33881577-32068AE7-D4F0-4B22-B9C6-15DC8E709AAFQ34119043-210D06FB-CAFD-40FF-90F7-7B6D5AD059EEQ34550268-68FA56D0-9FBE-4455-8FD8-B34A3C980993Q35008771-F2D30861-E45E-4B76-999C-1721DF349D74Q35058641-D82C0E9C-A51B-4562-BB9D-89CEF969733DQ35140466-58AEC82D-6D2F-4C7B-B36A-1C4652E35F00Q35294150-0DEF8702-B9D0-4C24-987D-6D5A23E3CB19Q35531454-A92F61D6-9343-48A0-8D4A-D214838FD0A2Q35659533-446141A7-401D-4703-83AF-394548EA8762Q35826747-8EF4539E-22FD-4E7B-8EDA-CEC78769FDDAQ36515541-EE8870D4-257F-48C6-AF77-44368E632DE2Q36978907-81A79BB0-ABFC-4B2A-8B1A-8FA54C3AB58DQ37713845-6E1608D6-E5D8-4458-BC2C-74AEFFF14AA8Q37987124-C64A116A-33E8-4538-A493-E106DCE3C2D5Q38045381-B46C01FB-EDF9-4B41-AF3E-A4942B2FBFCAQ38120526-5AB64F7D-6D55-4FDE-8F36-D6F7FA5F1329Q38201151-A99F1DC8-4696-4499-86B6-5C335FA7DD98Q38232105-BB9CA940-BC1F-418F-919B-1D22D7A027CCQ38636217-88C28B51-D248-4E80-A1D7-E8CBDE1ED1C2Q38749029-0B261ACB-A7E2-41C6-A0D4-0A3D0BA3A85FQ38794583-8A175DC8-4E30-4367-8FF4-A33B1DDAF6C5Q38983251-B6061D53-2599-438E-A228-1C1A31950BD1Q39184046-78D45795-2DB2-4F36-8C27-BD144F44532CQ40107607-6AFDFE83-BB10-4B9D-8558-65087599E62EQ40239323-30BA7447-8D7E-40AE-B0F3-8117A83C7F98Q40298293-D05E4599-090B-4800-9F46-9F0DC72EE88FQ41843303-3B63433B-3D42-4620-BF73-BCF9CD6E7B9AQ45046442-31A50E46-C777-4B1D-AA77-E2A1E60DA643Q47114154-A4720B0E-FBCD-4921-90CE-502CB3051623
P2860
How innate immune mechanisms contribute to antibody-enhanced viral infections
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
How innate immune mechanisms contribute to antibody-enhanced viral infections
@en
How innate immune mechanisms contribute to antibody-enhanced viral infections.
@nl
type
label
How innate immune mechanisms contribute to antibody-enhanced viral infections
@en
How innate immune mechanisms contribute to antibody-enhanced viral infections.
@nl
prefLabel
How innate immune mechanisms contribute to antibody-enhanced viral infections
@en
How innate immune mechanisms contribute to antibody-enhanced viral infections.
@nl
P2860
P356
P1476
How innate immune mechanisms contribute to antibody-enhanced viral infections
@en
P2093
Scott B Halstead
P2860
P304
P356
10.1128/CVI.00316-10
P577
2010-09-28T00:00:00Z